Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways.

Malpeli G, Barbi S, Tosadori G, Greco C, Zupo S, Pedron S, Brunelli M, Bertolaso A, Scupoli MT, Krampera M, Kamga PT, Croce CM, Calin GA, Scarpa A, Zamò A.

Oncotarget. 2018 Jul 3;9(51):29753-29771. doi: 10.18632/oncotarget.25707. eCollection 2018 Jul 3.

2.

Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells.

Volinia S, Bertagnolo V, Grassilli S, Brugnoli F, Manfrini M, Galasso M, Scatena C, Mazzanti CM, Lessi F, Naccarato G, Caligo A, Bianchini E, Piubello Q, Orvieto E, Rugge M, Natali C, Reale D, Vecchione A, Warner S, Croce CM, Capitani S.

Oncotarget. 2018 May 4;9(34):23543-23553. doi: 10.18632/oncotarget.25261. eCollection 2018 May 4.

3.

MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma.

Malpeli G, Barbi S, Greco C, Zupo S, Bertolaso A, Scupoli MT, Krampera M, Kamga PT, Croce CM, Scarpa A, Zamò A.

Oncotarget. 2018 Apr 13;9(28):19961-19979. doi: 10.18632/oncotarget.24987. eCollection 2018 Apr 13.

4.

Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma.

Moshiri F, Salvi A, Gramantieri L, Sangiovanni A, Guerriero P, De Petro G, Bassi C, Lupini L, Sattari A, Cheung D, Veneziano D, Nigita G, Shankaraiah RC, Portolani N, Carcoforo P, Fornari F, Bolondi L, Frassoldati A, Sabbioni S, Colombo M, Croce CM, Negrini M.

Oncotarget. 2018 Feb 27;9(20):15350-15364. doi: 10.18632/oncotarget.24601. eCollection 2018 Mar 16.

5.

Hsa-miR-155-5p drives aneuploidy at early stages of cellular transformation.

Pagotto S, Veronese A, Soranno A, Lanuti P, Marco MD, Russo MV, Ramassone A, Marchisio M, Simeone P, Franchi PEG, Palka G, Costantini RM, Croce CM, Visone R.

Oncotarget. 2018 Feb 7;9(16):13036-13047. doi: 10.18632/oncotarget.24437. eCollection 2018 Feb 27.

6.

Mutation of TGFβ-RII eliminates NSAID cancer chemoprevention.

Martín-López J, Gasparini P, Coombes K, Croce CM, Boivin GP, Fishel R.

Oncotarget. 2017 Dec 31;9(16):12554-12561. doi: 10.18632/oncotarget.23792. eCollection 2018 Feb 27.

7.

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.

Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R.

Oncotarget. 2017 Dec 12;9(4):4354-4365. doi: 10.18632/oncotarget.23150. eCollection 2018 Jan 12.

8.

Integration of metabolomics, transcriptomics, and microRNA expression profiling reveals a miR-143-HK2-glucose network underlying zinc-deficiency-associated esophageal neoplasia.

Fong LY, Jing R, Smalley KJ, Taccioli C, Fahrmann J, Barupal DK, Alder H, Farber JL, Fiehn O, Croce CM.

Oncotarget. 2017 Jun 9;8(47):81910-81925. doi: 10.18632/oncotarget.18434. eCollection 2017 Oct 10.

9.

ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer.

Zhou JK, Zheng YZ, Liu XS, Gou Q, Ma R, Guo CL, Croce CM, Liu L, Peng Y.

Oncotarget. 2017 May 16;8(20):32864-32872. doi: 10.18632/oncotarget.15860.

10.

MicroRNAs in melanoma development and resistance to target therapy.

Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, Mancini R, Ciliberto G.

Oncotarget. 2017 Mar 28;8(13):22262-22278. doi: 10.18632/oncotarget.14763. Review.

11.

Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53.

Malpeli G, Barbi S, Zupo S, Tosadori G, Scardoni G, Bertolaso A, Sartoris S, Ugel S, Vicentini C, Fassan M, Adamo A, Krampera M, Scupoli MT, Croce CM, Scarpa A.

Oncotarget. 2017 Feb 14;8(7):11809-11826. doi: 10.18632/oncotarget.14683.

12.

A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy.

D'Avino C, Palmieri D, Braddom A, Zanesi N, James C, Cole S, Salvatore F, Croce CM, De Lorenzo C.

Oncotarget. 2016 Dec 27;7(52):87016-87030. doi: 10.18632/oncotarget.13522.

13.

Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias.

Sattari A, Siddiqui H, Moshiri F, Ngankeu A, Nakamura T, Kipps TJ, Croce CM.

Oncotarget. 2016 Aug 23;7(34):54174-54182. doi: 10.18632/oncotarget.11099.

14.

MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.

Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, Menna G, Santoro N, Zecca M, Basso G, Nigita G, Veneziano D, Pagotto S, D'Ovidio K, Rota R, Dorrance A, Croce CM, Niemeyer C, Locatelli F, Garzon R.

Oncotarget. 2016 Aug 23;7(34):55395-55408. doi: 10.18632/oncotarget.10577.

15.

A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.

Gaudio E, Paduano F, Ngankeu A, Ortuso F, Lovat F, Pinton S, D'Agostino S, Zanesi N, Aqeilan RI, Campiglia P, Novellino E, Alcaro S, Croce CM, Trapasso F.

Oncotarget. 2016 May 24;7(21):29927-36. doi: 10.18632/oncotarget.9179.

16.

FoxO1 regulates allergic asthmatic inflammation through regulating polarization of the macrophage inflammatory phenotype.

Chung S, Lee TJ, Reader BF, Kim JY, Lee YG, Park GY, Karpurapu M, Ballinger MN, Qian F, Rusu L, Chung HY, Unterman TG, Croce CM, Christman JW.

Oncotarget. 2016 Apr 5;7(14):17532-46. doi: 10.18632/oncotarget.8162.

17.

MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors.

Rossi M, Colecchia D, Ilardi G, Acunzo M, Nigita G, Sasdelli F, Celetti A, Strambi A, Staibano S, Croce CM, Chiariello M.

Oncotarget. 2016 Apr 12;7(15):20981-98. doi: 10.18632/oncotarget.8044.

18.

Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells.

Palmieri D, Scarpa M, Tessari A, Uka R, Amari F, Lee C, Richmond T, Foray C, Sheetz T, Braddom A, Burd CE, Parvin JD, Ludwig T, Croce CM, Coppola V.

Oncotarget. 2016 Apr 5;7(14):18371-83. doi: 10.18632/oncotarget.7813.

19.

MicroRNA dysregulation and esophageal cancer development depend on the extent of zinc dietary deficiency.

Fong LY, Taccioli C, Jing R, Smalley KJ, Alder H, Jiang Y, Fadda P, Farber JL, Croce CM.

Oncotarget. 2016 Mar 8;7(10):10723-38. doi: 10.18632/oncotarget.7561.

20.

miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS.

Fiore D, Donnarumma E, Roscigno G, Iaboni M, Russo V, Affinito A, Adamo A, De Martino F, Quintavalle C, Romano G, Greco A, Soini Y, Brunetti A, Croce CM, Condorelli G.

Oncotarget. 2016 Apr 12;7(15):19531-47. doi: 10.18632/oncotarget.6968.

Supplemental Content

Loading ...
Support Center